Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) has exemplified the advancement of precision oncology, yet inevitable resistance to tyrosine kinase inhibitors (TKIs) remains a challenge. Here, EGFR is linked to non-small cell lung carcinoma.